CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients

Neurobiology of Aging

Volumn 34, Issue 3, 2013, Pages 805-808

  Solas, Maite ^a   Francis, Paul T ^b   Franco, Rafael ^c,d   Ramirez, Maria J ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

A levels; Amyloid plaques; CB1 receptor; Cognitive status; Hypophagia; Neurofibrillary tangles

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CANNABINOID 2 RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; AMYLOID BETA PROTEIN; CANNABINOID 1 RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; COGNITION; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GLIA CELL; HUMAN; HUMAN TISSUE; HYPOPHAGIA; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; AMYLOID PLAQUE; CASE CONTROL STUDY; COHORT ANALYSIS; FRONTAL LOBE; GLIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FRONTAL LOBE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; NEUROGLIA; PLAQUE, AMYLOID; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84870574017     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.06.005     Document Type: Article

References (14)

1. Benito C., Núñez E., Tolón R.M., Carrier E.J., Rábano A., Hillard C.J., Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci 2003, 23:11136-11141.
2. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials [erratum in 2008;371:558]. Lancet 2007, 370:1706-1713.
3. Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?. Biol. Psychiatry 2010, 68:876-878.
4. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198.
5. Garcia-Alloza M., Tsang S.W., Gil-Bea F.J., Francis P.T., Lai M.K., Marcos B., Chen C.P., Ramirez M.J. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol. Aging 2006, 27:1110-1117.
6. Grünblatt E., Zander N., Bartl J., Jie L., Monoranu C.M., Arzberger T., Ravid R., Roggendorf W., Gerlach M., Riederer P. Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J. Alzheimers Dis 2007, 12:291-311.
7. Heneka M.T., O'Banion M.K., Terwel D., Kummer M.P. Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm 2010, 117:919-947.
8. Hope T., Fairburn C.G. The Present Behavioural Examination (PBE): the development of an interview to measure current behavioural abnormalities. Psychol. Med 1992, 22:223-230.
9. Lai M.K., Lai O.F., Keene J., Esiri M.M., Francis P.T., Hope T., Chen C.P. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 2001, 57:805-811.
10. Lee J.H., Agacinski G., Williams J.H., Wilcock G.K., Esiri M.M., Francis P.T., Wong P.T., Chen C.P., Lai M.K. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem. Int 2010, 57:985-989.
11. Lewis D.A. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 2002, 26:143-154.
12. Marcos B., García-Alloza M., Gil-Bea F.J., Chuang T.T., Francis P.T., Chen C.P., Tsang S.W., Lai M.K., Ramirez M.J. Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer's disease. J. Alzheimers Dis 2008, 14:43-50.
13. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci 2005, 25:1904-1913.
14. Tolón R.M., Núñez E., Pazos M.R., Benito C., Castillo A.I., Martínez-Orgado J.A., Romero J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 2009, 1283:148-154.